Showing 1-6 of 6 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Demand for Combined CGM-Pump Devices in Type 1 Diabetes | Magnolia Innovation, LLC | Kenneth Howie | Improving Lives | 01-August-2025 to 15-February-2026 | $291,000.00 |
| T1D Adjunct Therapy Product & Patient Profiling Study | Magnolia Innovation, LLC | Kenneth Howie | Improving Lives | 01-December-2024 to 30-September-2025 | $434,000.00 |
| Comprehensive Landscape Study on Biomaterials in T1D | Quaestio Global Partners, LLC | Magdy Abdel-Malik | Cures | 14-March-2025 to 30-June-2025 | $55,000.00 |
| The master regulator transcription factor, Zbtb20, defines and controls a regulatory T cell subset that controls tissue inflammation. | Rutgers Biomedical and Health Sciences | Derek Sant’Angelo | Cures | 01-March-2023 to 28-February-2026 | $935,026.00 |
| Treating Type 1 Diabetes: Role of Kisspeptin | Rutgers Biomedical and Health Sciences | Moshmi Bhattacharya | Cures | 01-April-2024 to 31-March-2026 | $140,000.00 |
| PREdictors for DiabetIC Ketoacidosis at Diagnosis of Type 1 Diabetes (The PREDICT study) | Rutgers, The State University of New Jersey | Chintan Dave | Cures | 01-August-2022 to 31-July-2025 | $695,404.04 |